Wednesday, August 27th, 2025
Stock Profile: THAR
THAR Logo

Tharimmune, Inc. (THAR)

Market: NASD | Currency: USD

Address: 1200 Route 22 East

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas Show more




📈 Tharimmune, Inc. Historical Chart






📊 Statistics





💰 Dividend History


Year Annual Yield (%) Total Amount Current Yield (%) Ex Date Pay Date Particulars
2024 - $0.066667 - 2024-05-28 - Stock split
Total Amount for 2024: $0.066667
2023 - $0.040000 - 2023-11-21 - Stock split
Total Amount for 2023: $0.040000


📅 Earnings & EPS History for Tharimmune, Inc.


DateReported EPS
2025-05-12-
2025-03-26-
2024-11-07-
2024-08-09-
2024-08-08-
2024-05-09-
2024-05-08-
2024-02-23-0.71
2024-02-22-0.71
2023-11-07-0.11
2023-11-06-0.11




📰 Related News & Research


No related articles found for "tharimmune inc".